Tissue Screening and Diagnosis of Transthyretin Amyloid Cardiomyopathy
Reviews in Cardiovascular Medicine · 29.06.2026 · 27 (6)
DOI: 10.31083/rcm50854 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 29.06.2026. Verfasst von Ryan Tang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Given the multi-organ involvement of transthyretin (ATTR) amyloidosis, associated symptoms such as peripheral neuropathy, biceps tendon rupture, lumbar stenosis, and bilateral carpal tunnel syndrome can develop concurrently with cardiac disease or even precede the cardiac diagnosis by up to a decade. Screening of tissue obtained opportunistically during an otherwise indicated procedure or diagnostic test has shown promise for the early identification of nascent cardiac amyloidosis (CA) in patients who might otherwise remain undiagnosed for years. This review aims to: (1) briefly summarize the cardiac and non-cardiac manifestations of transthyretin cardiomyopathy (ATTR-CM) that may raise clinical suspicion for the disease; (2) discuss tissue-based screening within contemporary ATTR-CM diagnostic pathways; (3) describe the diagnostic yield and management challenges of tissue screening, with a focus on early detection; (4) examine the treatment and surveillance implications of tissue screening in both symptomatic and asymptomatic individuals. Multidisciplinary collaboration (e.g., partnerships between hand surgery centers and amyloid centers) and criteria-based screening of specimens obtained during noncardiac and cardiac surgery may offer an effective strategy for identifying patients earlier in the associated disease course. However, given the variable diagnostic yield, the significant anxiety associated with comprehensive evaluation for ATTR-CM, and the potentially high cost of treating CA with one of the three therapies approved by the Food and Drug Administration (FDA), further refinement of screening criteria and additional investigation into the impact of early treatment on disease trajectory and outcomes are needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
- George and Linda Kaufman Center for Heart Failure and Recovery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
- Amyloidosis Center, Cleveland Clinic, Cleveland, OH 44195, USA.
- Department of Cardiovascular Medicine, Cleveland Clinic Florida, Weston, FL 33331, USA.
ORCID-Profile: Ryan Tang, Harsh Patolia, Judah Rajendran, Michel Chedid El Helou, Andres Carmona Rubio, Mazen Hanna, Trejeeve Martyn
Zitieren
APA
Tang, R., Patolia, H., Shukla, N., Rajendran, J., El Helou, M. C., Agdamag, A., Estep, J. D., Rubio, A. C., Hanna, M., & Martyn, T. (2026). Tissue Screening and Diagnosis of Transthyretin Amyloid Cardiomyopathy. Reviews in Cardiovascular Medicine, 27(6). https://doi.org/10.31083/rcm50854
Vancouver
Tang R, Patolia H, Shukla N, Rajendran J, El Helou MC, Agdamag A, et al. Tissue Screening and Diagnosis of Transthyretin Amyloid Cardiomyopathy. Reviews in Cardiovascular Medicine. 2026;27(6). doi:10.31083/rcm50854
BibTeX
@article{Tang2026,
author = {Tang, Ryan and Patolia, Harsh and Shukla, Neehal and Rajendran, Judah and El Helou, Michel Chedid and Agdamag, Arianne and Estep, Jerry D and Rubio, Andres Carmona and Hanna, Mazen and Martyn, Trejeeve},
title = {Tissue Screening and Diagnosis of Transthyretin Amyloid Cardiomyopathy},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
volume = {27},
number = {6},
doi = {10.31083/rcm50854}
}
EUVIMED